Park Square Financial Group LLC Acquires Shares of 1,577 Eli Lilly and Company (NYSE:LLY)

Park Square Financial Group LLC purchased a new position in Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,577 shares of the company's stock, valued at approximately $1,218,000. Eli Lilly and Company comprises 0.8% of Park Square Financial Group LLC's portfolio, making the stock its 26th biggest holding.

A number of other hedge funds have also modified their holdings of the stock. FPC Investment Advisory Inc. lifted its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $50,000. Fiduciary Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $58,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $63,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $17.73 during trading on Friday, reaching $740.30. 2,133,782 shares of the company's stock traded hands, compared to its average volume of 3,621,131. The company has a market capitalization of $701.61 billion, a P/E ratio of 63.06, a PEG ratio of 1.40 and a beta of 0.48. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm's 50-day moving average is $779.13 and its 200 day moving average is $800.51. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.58 earnings per share. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.81%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Finally, Truist Financial upped their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,011.37.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.